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Background: Induced pluripotent stem cells (iPSCs) constitute an attractive source of cells for regenerative medicine.
Results:MicroRNA-21 mediates endothelial differentiation derived from iPSCs in presence of VEGF.
Conclusion:MicroRNA-21 and TGF-2 signaling pathways regulate iPSC differentiation to endothelial lineage.
Significance:Elucidation of themolecularmechanisms underlyingmicroRNA-21-regulated iPSCdifferentiationmight provide
the basic information for stem cell therapy of vascular diseases.
Finding a suitable cell source for endothelial cells (ECs) for
cardiovascular regeneration is a challenging issue for regenera-
tive medicine. In this paper, we describe a novel mechanism
regulating induced pluripotent stem cells (iPSC) differentiation
into ECs, with a particular focus on miRNAs and their targets.
We first established a protocol using collagen IV and VEGF to
drive the functional differentiation of iPSCs into ECs and com-
pared the miRNA signature of differentiated and undifferenti-
ated cells. Among the miRNAs overrepresented in differenti-
ated cells, we focused onmicroRNA-21 (miR-21) and studied its
role in iPSC differentiation. Overexpression of miR-21 in pre-
differentiated iPSCs induced EC marker up-regulation and in
vitro and in vivo capillary formation; accordingly, inhibition of
miR-21 produced the opposite effects. Importantly, miR-21
overexpression increased TGF-2 mRNA and secreted protein
level, consistent with the strong up-regulation of TGF-2
during iPSC differentiation. Indeed, treatment of iPSCs with
TGF-2 induced ECmarker expression and in vitro tube forma-
tion. Inhibition of SMAD3, a downstream effector of TGF-2,
stronglydecreasedVE-cadherinexpression.Furthermore,TGF-2
neutralization and knockdown inhibited miR-21-induced EC
marker expression. Finally, we confirmed the PTEN/Akt path-
way as a direct target of miR-21, and we showed that PTEN
knockdown is required formiR-21-mediated endothelial differ-
entiation. In conclusion, we elucidated a novel signaling path-
way that promotes the differentiation of iPSC into functional
ECs suitable for regenerative medicine applications.
Endothelial cells (ECs)3 line the blood vessels of the entire
circulatory system and represent the barrier between circulat-
ing blood and the rest of the vessel wall. The endothelium is a
dynamic and heterogeneous organ with secretory, metabolic,
synthetic, and immunological functions (1). There are two
main mechanisms that lead to blood vessel formation, namely
vasculogenesis and angiogenesis. Vasculogenesis is the forma-
tion of new vessels from progenitor cells and was historically
believed to occur in embryo development, during the formation
of the primitive vascular network from angioblasts (2). Angio-
genesis is the formation of new blood vessels from pre-existing
ones and occurs both during embryonic development and dur-
ing physiological and pathological conditions in adult life.
Angiogenesis in the infarcted tissue occurs through a complex
link between extracellular matrix, ECs, and pericytes, in
response to an imbalance of angiogenic factors, compared with
angiostatic factors in the local environment (3, 4).
Atherosclerosis is a chronic inflammatory disease, started by
endothelial dysfunction, that leads to the formation of an ath-
erosclerotic plaque (5, 6). Balloon angioplasty and stenting are
routinely used in clinical practice to treat these conditions.
However, one of the major issues of stenting is restenosis, lead-
ing to the recurrence of symptoms through EC loss and subse-
quent smoothmuscle proliferation andmatrix deposition, thus
originating luminal narrowing (7). It has been reported that
after vascular injury, restenosis development can be prevented
through accelerated re-endothelialization by mature ECs,
which inhibits smooth muscle migration, proliferation, and
neointima formation (8). In the past several years, accumulat-
ing evidence suggests that ES cells, a promising source of plu-
ripotent stemcellswith unlimited growth and self-renewal abil-
ities, are able to differentiate into ECs in vitro and in vivo (9).
The ethical and immunological problems associated with the
use of ES cells have been recently bypassed using induced plu-
ripotent stem cells (iPSCs), because they can be derived from
somatic cell population isolated from the patient. In this study,
we indeed aimed at understanding the molecular mechanisms
of iPSC differentiation into ECs, to define newmethods to pro-
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duce large number of ECs with high purity from iPSCs: iPSC-
derived ECs can be used to treat damaged vessels, to avoid rest-
enosis, and to develop tissue engineered vascular grafts, now
major challenges for the future of regenerative medicine (10).
miRNAs are single-stranded, noncoding molecules of RNA,
20–25 nucleotides long, able to regulate a wide range of cellular
processes by binding to noncoding regions of mRNA (11).
Recent studies focused on angiogenesis-associated miRNAs
that are involved in ES cells differentiation toward ECs (12). It
has been recently reported that miR-21 overexpression in
human prostate cancer cells increased hypoxia-inducible fac-
tor-1 (HIF-1) andVEGF expression, thereby inducing tumor
angiogenesis (13). On the other hand, miR-21 has been shown
to have antiangiogenic functions, targeting RhoB in ECs (14)
and TGF-RII in human adipose-derived stem cells (hADSCs),
thus decreasing the tumor vascularity induced by the cells (15).
In addition, in endothelial progenitor cells, miR-21 has been
found to induce cell senescence and reduce angiogenesis in
vitro and in vivo (16). In addition to the role of miR-21 in angio-
genesis, miR-21 has been also shown to induce adipogenic dif-
ferentiation of hADSCs via targeting TGF-RII (17). However,
so far there are no studies showing a link between miR-21 and
endothelial differentiation from iPSCs.
TGF- is a multifunctional cytokine that regulates prolifera-
tion, migration, differentiation, and survival of many different
cell types. Deletion or mutation of different members of the
TGF- family have been shown to cause vascular remodeling
defect and absence of mural cell formation, leading to embry-
onic lethality (18) or severe vascular disorders (19, 20). It has
been previously demonstrated that stimulation of hADSCs
with TGF-2 increased the levels of VEGF and interleukin-6,
thus promoting the proangiogenic action of the cells in a hind
limb ischemiamodel (15). However, no previous report showed
an involvement of TGF- in endothelial differentiation of
iPSCs. In particular, we focused on the study of one of the three
known isoforms of TGF-, TGF-2. In the present study, we
described a novel protocol for iPSC differentiation into ECs,
and we elucidated the role of miR-21 in mediating this process,
through targeting-specific pathways. We highlighted for the
first time, to our knowledge, a connection betweenVEGF,miR-
21/Akt, and TGF-2 in the endothelial differentiation of iPSCs.
EXPERIMENTAL PROCEDURES
Materials—Cell culture media, serum, and cell culture sup-
plements were purchased from ATCC, Millipore, Invitrogen,
and PAA. Antibodies against VE-cadherin, Flk-1, eNOS, and
GAPDH were purchased from Abcam. Antibodies against
vWF, Akt 1/2, and Ser(P)-473 Akt were purchased from Santa
Cruz. Antibodies against CD31 were purchased from Abbiotec
and Santa Cruz. Antibody against PTEN was purchased from
New England Biolabs. The secondary antibodies for immuno-
staining anti-goat Alexa 488, anti-goat Alexa 594, and anti-rab-
bit Alexa 488, and anti-rabbit Alexa 594 were purchased from
Invitrogen. The secondary antibodies for Western blotting
were purchased from Dakocytomation.
Cell Culture, Differentiation, andTreatment of iPSCs—iPSCs
were generated in our laboratory starting from mouse embry-
onic fibroblasts isolated as stated in Ref. 21, using a similar
method stated in Ref. 22. iPSCswere cultured on gelatin-coated
flasks (PBS containing 0.04% of gelatin from bovine skin;
Sigma) in DMEM (ATCC) supplemented with 10% fetal bovine
serum, 100 IU/ml penicillin, and 100 g/ml streptomycin
(Invitrogen); 10 ng/ml recombinant human leukemia inhibi-
tory factor (Millipore); and 0.1 mM 2-mercaptoethanol (Invit-
rogen) in a humidified incubator supplemented with 5% CO2.
The cells were passaged every 2 days at a ratio of 1:6. Differen-
tiation of iPSCs was obtained by seeding the cells on type IV
mouse collagen (5 g/ml)-coated dishes in differentiation
medium (DM) that contains -MEM supplemented with 10%
FBS (Invitrogen), 0.05 mM 2-mercaptoethanol, 100 units/ml
penicillin, and 100 g/ml streptomycin. The medium was sup-
plemented with 50 ng/ml VEGF or 3 ng/ml TGF-2 (Pepro-
tech), and the cells were maintained under these conditions for
up to 7 days. 5MSMAD3 inhibitor SIS3 (Calbiochem), and 0.1
g/ml VEGF neutralizing antibody (R&D System) were added
to iPSCs cultured for 7 days with TGF-2; 1 g/ml TGF-2
neutralizing antibody (R&D System) was added to the cells 24 h
after transfection with pre-miR-21 (Pre-21) for further 24 h.
The number of iPSCs seeded on collagen IV for the differenti-
ation was 1.3  104/cm2 (d3), 6.6  103/cm2 (d5), and 3.3 
103/cm2 (d7).
Quantitative RT-PCR—Relative gene expression was deter-
mined by quantitative real time PCR, using 2 ng of cDNA (rel-
ative to RNA amount) for each sample with the SYBR Green
Master Mix in a 20-l reaction. Ct values were measured using
ABI Prism 7000 sequence detector (Applied Biosystems). The
18 S ribosomal RNA served as the endogenous control to nor-
malize the amounts of RNA in each sample. For each sample,
PCR was performed in duplicate in a 96-well reaction plate
(Eppendorf, twin.tec real time PCR plates). The gene was con-
sidered undetectable beyond 35 cycles. The primer sets used for
this study are as follows: 18 S, forward, 5-CCAGTAAGT-
GCGGGTCATAA-3 and reverse, 5-CCGAGGGCCTCACT-
AAACC-3; VE-cadherin, forward, 5-AAGAAACCGCTGA-
TCGGCA-3 and reverse, 5-TCGGAAGAATTGGCCTCT-
GTC-3; CD31, forward, 5-CAAACAGAAACCCGTGGAGAT-3
and reverse, 5-ACCGTAATGGCTGTTGGCTTC-3; Flk-1,
forward, 5-TGAAATTGAGCTATCTGCCGG-3 and re-
verse, 5-TTTGAAGGTGGAGAGTGCCAG-3; vWF, forwa-
rd, 5-GGCTGTGCGGTGATTTTAACAT-3 and reverse, 5-
CGTTTACACCGCTGTTCCTCA-3; and TGF-2, forward,
5-CTTCGACGTGACAGACGCT-3 and reverse, 5-GCA-
GGGGCAGTGTAAACTTATT-3.
miRNA Extraction, Reverse Transcription, Preamplification,
and TaqMan Quantitative PCR Assay—Extraction of total
RNA including miRNA was performed using the miRNeasy
mini kit (Qiagen), according to the manufacturer’s protocol.
miRNA reverse transcription and amplification were per-
formed using the Megaplex reverse transcription primers
(rodent pools A andB, v3.0) and theMegaplex PreAmpprimers
(rodent primers A and B, v3.0) (Applied Biosystems) as previ-
ously described (23). TaqMan miRNA assays were used to
assess the expression of individual miRNAs as described before
(23).
miR-21 Transient Transfection—Manipulation of miR-21
levels in iPSCs differentiated in presence ofVEGF for 3 days and
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cultured to 60–70% confluencewas performed using Pre-21, or
the nontargeting control (Pre-ctrl) (AmbionAB), whereas inhi-
bition of miR-21 was performed using the locked nucleic acid
(LNA) inhibitor of miR-21 (LNA-21) or a negative control
(LNA-ctrl) (Exiqon). All transfections were performed using
LipofectamineTM RNAiMAX (Invitrogen), in accordance with
the manufacturer’s protocol.
TaqMan miRNA Array—The expression profile of miRNAs
in the samples was determined using the rodent TaqMan
miRNA arrays A and B (Applied Biosystems), which is a set of
two 384-well microfluidic cards (arrays A and B, v3.0). The
arrays enable quantification of gene expression levels of 375
miRNAs per pool and are specific to human,mouse, or rat. Five
endogenous controls and a negative control were included in
each array for data normalization. PCRs were performed using
450l of theTaqManUniversal PCRMasterMixNoAmpErase
UNG (2) and 9l of the diluted preamplification product to a
final volume of 900 l. 100 l of the PCR mix were loaded to
each port of the TaqMan miRNA array. The fluidic card was
then centrifuged and mechanically sealed. Real time PCR was
carried out on an Applied Biosystems 7900HT thermocycler
using the manufacturer’s recommended program.
Immunoblotting and Immunofluorescent Staining—For West-
ern blot analysis, cell pellets were resuspended in radioimmune
precipitation assay buffer and sonicated. The protein concen-
tration was measured by the Bradford method. 20–50 g of
each sample was loaded on 6–8% polyacrylamide gels, and
standard immunoblotting procedure was performed using the
listed primary antibodies.
Immunostaining was performed as described previously
(24). Adherent cells were fixed in 4% buffered paraformalde-
hyde and permeabilized (in the case of intracytoplasmatic anti-
gens) with 0.1% Triton X prior and blocked in 1% BSA before
incubation with primary antibody for VE-cadherin, CD31,
vWF, and eNOS.
In Vitro and in Vivo Tube Formation Assay—iPSCs were dif-
ferentiated in the presence of VEGF for 4 days and then trans-
fected with Pre-21, Pre-ctrl, LNA-21, and LNA-ctrl. In vitro
angiogenesis assays was performed after 48 h as described pre-
viously (25); in vitro angiogenesis assay was also performed
after 7 days of differentiation in the presence of VEGF or
TGF-2 treatment. In vivo angiogenesis was performed 48 h
after miR-21 transfection bymixing 5 105 cells with 200l of
Matrigel and injecting it subcutaneously in mice (C57BL/6).
The cryosections of theMatrigel plugs were stained with CD31
and VE-cadherin antibodies. Immunostaining was assessed by
confocal imaging, and capillary density was calculated as the
number of capillary number/mm2.
Mice—All procedures were performed according to proto-
cols approved by the Institutional Committee for Use and Care
of Laboratory Animals. All animals used in this study were
inbred mice of C57BL/6 background.
Luciferase Reporter Assay—For the luciferase reporter assays,
3 104 iPSCs cells were seeded in each collagen-coated well of
a12-well plate in DM containing VEGF. 72 h later, cells were
transfected with the plasmid expressing luciferase under the
control of the PTEN 3-UTR (pGL3-PTEN-wt) and the miR-21
inhibitor and its control. As a control, the same experiment was
performed with a plasmid expressing luciferase under the con-
trol of a mutated and inactive PTEN 3-UTR (pGL3-PTEN-
mut). Briefly, 0.33 g/well of the reporter plasmids (AddGene,
Joshua Mendell laboratory (26)) were co-transfected with the
miR-21 inhibitor and the inhibitor negative control using
jetPRIME® (2 l/well) (Polyplus-transfection SA) according to
the protocol provided. 48 h after transfection, luciferase activity
wasmeasured using the dual luciferase assay system (Promega).
The firefly luciferase activity of each sample was normalized to
Renilla luciferase activity.
shRNA Lentiviral Particle Transduction—Lentiviral particles
were produced by transfecting HEK 293T with shPTEN pLKO.1
plasmid (Sigma Mission) or shTGF-2 as described previously
(27). Knockdown of PTEN and TGF-2was achieved by infect-
ing iPSCs differentiated for 3 days in presence of VEGF with
PTEN and TGF-2 shRNA lentiviruses, respectively (shPTEN
and shTGF-2). Cells were infected with shPTEN, shTGF-2,
or the nontargeting control (shNT) (107 transfection units/ml)
complete growth medium supplemented with 10 g/ml of
polybrene for 16–24 h. The viruses were then removed, and the
cells were transfected with LNA-21 and LNA-Ctrl or with
Pre-21 and Pre-Ctrl, as described before. Cells were harvested
for further analysis after 48 h.
Enzyme-linked Immunosorbent Assay—The concentration
of the VEGF and TGF-2 released glycoprotein in the superna-
tant was detected by VEGF and TGF-2 ELISA kits (Invitrogen
and R&D, respectively) according to the manufacturers’
protocol.
Statistical Analysis—Data expressed as the means  S.E.
were analyzed with a two-tailed Student’s t test for two groups
or pairwise comparisons. A value of p  0.05 was considered
significant.
RESULTS
VEGF Induces Functional Differentiation of iPSCs toward EC
Lineage—Wehave adapted previous protocol (24) to the differ-
entiation of mouse iPSCs by optimizing concentrations of
VEGF and differentiation time points (data not shown). Stim-
ulation of the cells with 50 ng/ml of VEGF rapidly induced a
marked change in the morphology of iPSCs, which lost their
three-dimensional organization and displayed a flat adherent
phenotype (Fig. 1, A and B). Protein analysis showed a consis-
tent up-regulation of endothelial markers such as CD31, Flk1,
and VE-cadherin, starting after 3 and 5 days of differentiation
and peaking at day 7 (Fig. 1C). Gene expression analysis con-
firmed this pattern of differentiation forVE-cadherin, Flk1, and
vWF (Fig. 1, D–F). Furthermore, staining for VE-cadherin,
eNOS, and vWF showed the localization of the proteins within
the cells and their homogeneous expression in the population
(Fig. 1, G–J). Finally, the functionality of ECs derived from
iPSCs was tested in an in vitro angiogenesis assay, showing a
significant increase in tubelike structure formation ability upon
cell differentiation, as comparedwith the cells grown in absence
of VEGF (Fig. 1, K–M). These findings indeed showed that the
protocol established allows the generation of a homogeneous
and functional population of endothelial cells from iPSCs.
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Characterization of miRNA Profile in iPSCs Differentiated to
ECs—To investigate the miRNA profile during vascular differ-
entiation of iPSCs, which might be involved in angiogenesis
(28), we performed a miRNA array in undifferentiated and dif-
ferentiated iPSCs for 3 days in the presence of 50 ng/ml VEGF;
we obtained two pools of differentially expressed miRNAs
(Table 1). Among the miRNAs that were most differentially
expressed, we chose to focus on miRNA-21. miR-21 has been
previously shown to be involved in angiogenesis (13–16) and
adipogenic differentiation of stem cells (17), but its role in stem
cell differentiation into endothelial cells remains to be eluci-
dated. Real time PCR confirmed the overexpression of miR-21
starting at day 3 and peaking at days 5 and 7 (Fig. 2A). To study
its role in differentiation, we transfected the cells after 3 days of
culture in the presence of VEGFwithmiR-21 precursor and the
precursor negative control (Pre-21 and Pre-Ctrl; Fig. 2B) or
miR-21 inhibitor and the inhibitor control (LNA-21 and LNA-
Ctrl; Fig. 2C) and analyzed the expression levels of endothelial
markers. Overexpression of miR-21 significantly induced
VE-cadherin and Flk1 gene expression (Fig. 2, D and E). Con-
sistently, protein analysis confirmed the induction of the pro-
tein levels of VE-cadherin andCD31 (Fig. 2, F andG). Although
miR-21 inhibition did not affect the gene expression of the EC
markers (Fig. 2, H and I), it led to a significant decrease in the
protein induction of these markers (Fig. 2, J and K). Even
though we should expect a decrease in protein levels derived
from RNA levels, the translational efficiency is differentially
affected in the inhibitory system. Moreover, these differentia-
tion markers are indirect targets of the miR-21; the effect on
their expression is therefore mediated by other pathways.
Importantly, miR-21 did not affect EC marker expression in
the absence of VEGF stimulation (data not shown); this result
indicates that VEGF stimulation is required to initiate the dif-
ferentiation process toward an endothelial progenitor cell pop-
ulation in which miR-21 induction is able to further induce the
EC marker up-regulation. Moreover, no effect of miR-21 over-
expression was detected for smooth muscle markers and other
mesoderm, endoderm, and ectoderm lineagemarkers (data not
shown).
Next, miR-21 transfected cells were tested in in vitro and in
vivo angiogenesis assays. Overexpression of miR-21 induced
the formation of tubelike structures in vitro (Fig. 3,A–C). Inclu-
sion ofmiR-21-overexpressing cells in in vivoMatrigel plugs led
to the formation of a significantly higher number of CD31 and
FIGURE 1.VEGF induces functional differentiation of iPSCs into ECs. A–J, iPSCswere cultured on collagen IV and in DM supplementedwith 50 ng/ml VEGF,
followed by morphological analysis (iPSCs undifferentiated on gelatin used as a control (A) and iPSC-derived ECs (B); scale bar, 25 m), Western blotting (C),
quantitative RT-PCR assay (D–F), (day 0 (d0) corresponds to the undifferentiated cells), and immunofluorescence staining (negative controls consisted of cells
incubated with IgG followed by secondary antibody; scale bar, 50m) (G–J). The results show the expression levels of the ECmarkers CD31, Flk1, VE-cadherin
(VE-cad), vWF, and eNOS. K–M, representative images of in vitro angiogenesis assay in iPSCs differentiated with or without VEGF for 7 days (DM and DM VEGF;
scale bar, 25 m) (K and L) and total tube length quantification (M). The data presented are representative of means S.E. (error bars) of three independent
experiments. **, p 0.01; ***, p 0.001.
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VE-cadherin capillaries, as compared with the plugs seeded
with precursor control transfected cells (Fig. 3, D–I). Accord-
ingly, miR-21 inhibition reduced the number of capillary struc-
tures both in vitro (Fig. 4, A–C) and in vivo (Fig. 4, D–I). These
results suggest that miR-21 is able to mediate a lineage-specific
effect on iPSCs treatedwith VEGF to boost their differentiation
into functional ECs.
Identification of theMolecular Targets ofmiRNA-21: TGF-2
Pathway Is aDownstreamTarget ofmiRNA-21 andDrives iPSC
Differentiation into ECs—Next, we aimed at elucidating the
molecular mechanisms involved in miR-21-mediated differen-
tiation of iPSCs. In silico predicted targets of miR-21 included
some proteins involved in the angiogenic process. Transfected
cells were analyzed for the expression of genes known to regu-
late EC functions and vessel growth, such as transforming
growth factor  receptor II (TGF-RII), regulator of ERK acti-
vation Sprouty 1 (SPRY1), RhoGTPase RhoB and Sox7, and
genes encoding regulators of cell migration such as vinculin. It
has been previously shown that in human adipose tissue-de-
rived mesenchymal stem cells miR-21 directly targets the
3-UTR of TGF-RII, thus inducing adipogenic differentiation
(17) or inhibiting tumor angiogenesis induced by the cells (15).
In particular, increased expression ofmiR-21 in hADSCs inhib-
its VEGFup-regulation induced byTGF- and therefore angio-
genesis (15). On the contrary, TGF-RII gene expression was
not decreased by miR-21 overexpression or increased by its
inhibition (data not shown). This result indicates that TGF-
RII is not directly targeted by miR-21 in ECs derived from
iPSCs. Furthermore, we tested expression of genes of the Wnt
and the HIF-1/VEGF signaling pathways, which are known
regulators of EC differentiation during embryogenesis and
tumor growth (29–31) (data not shown). Our results demon-
strated that VEGF expression was not inhibited by miR-21
overexpression or increased by its inhibition (data not shown);
therefore, VEGF is not a direct target of miR-21 during the
endothelial differentiation of iPSCs.
Additionally, we investigated the expression pattern of other
genes belonging to the TGF- family and found that TGF-2
was up-regulated bymiR-21 overexpression (Fig. 5A), although
not significantly down-regulated bymiR-21 inhibition (Fig. 5B).
Furthermore, ELISA result showed increased levels of secreted
TGF-2 in cells transfected with Pre-21 and reduced in cells
treated with miR-21 inhibitor (Fig. 5, C and D).
Analysis of TGF-2 expression in ECs derived from in iPSCs
showed a strong and significant induction of TGF-2 gene
expression, after 7 days of differentiation (Fig. 6A). This
increase wasmatched by the increase of its receptorsTGF-RII
and III (Fig. 6, B and C). Treatment of iPSCs with TGF-2
induced a statistically significant up-regulation of VE-cadherin
and Flk1 expression (Fig. 6, D and E). Western blotting con-
firmed these results for CD31 and VE-cadherin at the protein
level (Fig. 6, F andG).Moreover, iPSCs treatedwithTGF-2 for
7 days showed a significantly increased tube formation capac-
ity, as compared with untreated cells (Fig. 6, H–J). Importantly
TGF-2 treatment did not affect the smooth muscle marker
gene expression (data not shown).
To confirm the contribution of TGF-2 inmediatingmiR-21
effect on EC differentiation, Pre-21 transfected iPSCs were
treated with TGF-2 neutralizing antibody. TGF-2 neutral-
ization reduced the miR-21-induced VE-cadherin and CD31
expression at both gene and protein expression levels (Fig. 7, A
and B). To further confirm this result, we established a stable
knockdown of TGF-2 in iPSCs differentiated for 3 days in
presence of VEGF, using specific shRNAs. Following the
knockdown, cells were transfected with Pre-21, and ECmarker
expression was analyzed. TGF-2 gene expression showed a
significant repression after infection with shTGF-2, confirm-
ing the efficiency of the shRNA knockdown of TGF-2 (Fig.
7C). Importantly, in Pre-21 transfected cells, the gene expres-
sion levels ofVE-cadherin and Flk1 showed a significant reduc-
tion after shTGF-2 infection (Fig. 7, D and E). Remarkably, to
our knowledge, these findings are the first to suggest a role for
TGF-2 in the miR-21-mediated endothelial differentiation of
iPSCs.
To clarify themolecularmechanisms throughwhichTGF-2 is
able to drive iPSC differentiation into ECs, we focused on the
role of the TGF-2/SMAD3 pathway, which has been previ-
ously shown to mediate TGF--dependent ES cell differentia-
tion (32). Treatment of iPSCs with the SMAD3 inhibitor SIS3
significantly reduced VE-cadherin expression, in the presence
TABLE 1
MicroRNA array on iPSCs differentiated for 3 days with VEGF and
undifferentiated cells
The microRNA arrays were performed on iPSCs differentiated for 3 days on colla-
gen IV and in differentiation medium containing 50 ng/ml VEGF; undifferentiated
cells were used as control. The results represent averages of the differential expres-
sion between two independent experiments. In the panel are shown 28 and 7
microRNAs respectively up- and down-regulated at least 2-fold relative to the
undifferentiated iPSCs. miR-302a#, 34c#, and 92a# represent miR* passenger
strands. The results were obtained after normalization with three different endog-
enous controls (mouse small nucleolar RNA snoRNA202 and 135 and mammalian
MammU6). These microRNAs were initially characterized in mouse or rat (mmu,
Mus musculus; rno, Rattus norvegicus).
Target name snoRNA202 snoRNA135 MammU6
mmu-let-7c 6.7 3.4 4.9 3.2 6.8 1.9
mmu-miR-129–3p 33.9 15 22.6 6.2 39.1 25.9
mmu-miR-133a 7.2 4.4 5.3 3.9 7.2 2.8
mmu-miR-139–5p 3.6 2.5 2.3 1.3 4.2 3.7
mmu-miR-188–5p 3.3 0.5 2.3 0.7 3.5 0.4
mmu-miR-20b 3.1 1.6 2.1 0.7 3.6 2.6
mmu-miR-21 22.7 27.3 17.5 21.8 21.0 23.4
mmu-miR-218 2.9 0.5 2.1 0.7 3.1 0.3
mmu-miR-224 126.5 170.7 98.5 134.3 114.3 151.0
mmu-miR-26b 23.0 13.1 15.1 6.3 26.9 20.7
mmu-miR-29b 145.9 189.9 113.2 150.1 132.7 166.7
mmu-miR-302a 88.1 3.6 61.5 13.4 95.7 20.7
mmu-miR-302b 4,432 4,226 2,820 2,391 5,436 5,862
mmu-miR-302c 27,395 34,072 21,156 27,080 25,158 29,548
mmu-miR-340–5p 7.8 2.0 5.6 2.4 8.3 0.0
mmu-miR-34b-3p 6.6 1.1 4.7 1.1 7.1 0.6
mmu-miR-367 65.9 16.9 44.8 3.6 74.4 37.0
mmu-miR-449a 19.8 12.9 14.5 11.4 19.8 8.6
mmu-miR-685 2.9 0.2 2.0 0.2 3.2 1.1
rno-miR-224 9.3 5.1 6.1 2.4 10.8 8.2
hsa-miR-200b 2.0 0.6 2.0 0.3 2.5 0.6
mmu-miR-212 4.4 1.0 4.3 0.5 5.6 1.6
mmu-miR-2138 6.5 4.5 6.2 3.8 7.1 1.8
mmu-miR-302a# 108.1 46.1 104.7 34.8 129.4 9.8
mmu-miR-34c# 7.0 2.5 6.8 1.7 8.5 1.3
mmu-miR-374–5p 8.9 7.1 8.4 6.1 9.5 3.6
mmu-miR-449b 370.8 512.4 341.1 469.7 326.7 440.3
mmu-miR-92a# 4.1 2.1 3.9 1.7 4.7 0.1
mmu-miR-145 0.3 0.1 0.2 0.1 0.3 0.1
mmu-miR-467e 0.5 0.3 0.4 0.3 0.5 0.2
mmu-miR-669a 0.5 0.2 0.3 0.2 0.5 0.1
mmu-miR-409–3p 0.3 0.4 0.3 0.3 0.3 0.3
mmu-miR-467a 0.3 0.1 0.3 0.1 0.4 0.0
mmu-miR-690 0.4 0.1 0.3 0.1 0.4 0.0
mmu-miR-706 0.4 0.2 0.4 0.2 0.4 0.0
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or absence of TGF-2 (Fig. 7F). Furthermore, we analyzed the
effect of TGF-2 treatment on VEGF levels, based on previous
studies showing thatVEGF secretion is induced byTGF-2 (33,
34). ELISAs performed on iPSCs treated with TGF-2 for 7
days showed a significant induction in the VEGF secretion, as
compared with untreated cells (Fig. 7G). Additionally, in iPSCs
differentiated for 7 days with TGF-2 treatment, VEGF-block-
ing antibody reduced the TGF-2-dependent EC marker
expression (Fig. 7H). These data suggest that TGF-2 induces
EC differentiation in iPSCs through SMAD-dependent path-
way and by inducing VEGF secretion. However, TGF-2 treat-
ment of iPSCs was not able to induce miR-21 up-regulation
(data not shown). The result indicates that TGF-2 does not act
upstream of miR-21. These findings could indicate that addi-
tional pathways may also act together with TGF-2 to contrib-
ute to VEGF secretion, leading to maintenance of endothelial
differentiation state.
Identification of the Molecular Targets of miRNA-21: miR-21
Targets the PTEN/Akt Pathway, Which Regulates iPSC Differ-
entiation into ECs—One of the in silico predicted targets for
miR-21 is phosphatase and tensin homolog (PTEN). Recent
studies indicated that miR-21 inhibited the tumor suppressor
PTEN by binding to its 3-UTR (35). Inhibition of PTEN by
miR-21 has been reported to induce tumor angiogenesis
through Akt and ERK activation and HIF-1 expression (13).
Moreover, miR-21 has been shown to target PTEN/Akt and
partly mediate TGF--induced endothelial to mesenchymal
transition (36). However, so far the role of PTEN in miR-21-
mediated endothelial differentiation of iPSCs has not been elu-
cidated.We first confirmedPTEN as a direct target ofmiR-21 at
a protein expression level. In iPSCs differentiated with VEGF
for 3 days, transfection with Pre-21 caused a significant reduc-
tion of PTEN protein expression, whereas transfection with
LNA-21 led to a significant induction of PTEN (Fig. 8A).
Because PTEN is known to be the antagonist of PI3K, which
removes the 39 phosphate of phosphatidylinositol 1,4,5-tris-
phosphate, resulting in inhibition of the Akt signaling pathway
(37), we aimed to assess whether PTEN inhibition is required
for the activation of Akt during the miR-21-mediated iPSC dif-
ferentiation process. Concomitantly, previous data from our
group showed that the PI3K/Akt signaling pathway drives the
shear-induced ES cell differentiation into ECs (24). Our results
show that miR-21 overexpression increased the phosphoryla-
tion of Akt at the serine 473 site, whereas inhibition of miR-21
reduced Akt phosphorylation, as compared with the relative
negative controls. The total level of Akt was not significantly
altered bymiR-21 overexpression or inhibition (Fig. 8B). In par-
allel, to further confirm PTEN as a direct target of miR-21, we
FIGURE 2.miR-21 is up-regulated in iPSCs differentiatedwith VEGF and is able to regulate this process. A–C, iPSCswere differentiated for up to 7 days in
thepresenceof VEGF, followedbyTaqManquantitativePCRassay to analyze theexpressionofmaturemiR-21 (A). After 3daysof iPSCdifferentiationwithVEGF,
the levels of miR-21 were altered by transfecting the cells with precursor of miR-21 (Pre-21), negative control precursor (Pre-Ctrl) and inhibitor of miR-21
(LNA-21), and negative control inhibitor (LNA-Ctrl), followed by TaqMan quantitative PCR assay to assess the levels of mature miR-21 (B and C). D–G, quanti-
tative RT-PCR assay (D and E) and Western blotting (F, representative image; G, quantitative analysis) were performed 48 h after miR-21 overexpression. H–K,
quantitative RT-PCR assay (H and I) and Western blotting (J, representative image; K, quantitative analysis) were performed 48 h after miR-21 inhibition. The
expression levels of the endothelial markers VE-cadherin (VE-cad), Flk1, and CD31were assessed. The data presented are representative of means S.E. (error
bars) of three independent experiments. *, p 0.05; **, p 0.01; ***, p 0.001.
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performed a luciferase assay to assess the binding of miRNA to
mRNA. Co-transfection of theWT PTEN 3-UTR plasmid and
LNA-21 in iPSCs differentiating with VEGF resulted in a signif-
icant increase in luciferase activity (Fig. 8C). Importantly,
mutations in the sequence targeted bymiR-21 in PTEN 3-UTR
abolished the observed up-regulation of luciferase activity by
miR-21 (Fig. 8D). These results confirmed PTEN as a direct
target of miR-21 and validated its specific binding to the pre-
dicted binding site.
We therefore decided to assess whether the PTEN/Akt path-
way was essential in driving miR-21-mediated iPSC differenti-
ation into EC. We indeed aimed to establish a stable knock-
down of PTEN in iPSCs differentiatedwithVEGF using specific
shRNAs, to then analyze the ECmarker expression. PTEN gene
expression showed a significant repression in iPSCs infected
with shPTEN, confirming the efficiency of the shRNA knock-
down of PTEN. Importantly, VE-cadherin and Flk1 showed a
statistically significant increase in the gene expression after
shPTEN infection (Fig. 8E).We then analyzed the expression of
the EC markers in iPSCs treated with VEGF and transfected
with LNA-21, using shPTEN. PTENprotein expression showed
a significant down-regulation in iPSCs infected with shPTEN,
confirming the efficiency of the shRNA knockdown of PTEN
(Fig. 8F). Our results also showed that in LNA-21 transfected
cells, the protein levels of VE-cadherin were significantly
increased after shPTEN infection (Fig. 8F).
These data suggest that during EC differentiation of iPSCs,
miR-21 inhibits PTEN expression, which in turn increases Akt
phosphorylation. The results presented in this study also high-
light that PTEN inhibition is required for miR-21mediated up-
regulation of EC markers in differentiated iPSCs.
DISCUSSION
Regeneration of damaged vessels and promotion of new ves-
sel formation in infarcted tissues require the identification of a
suitable source of ECs that can be derived from the patient in
adequate number for clinical use. Somatic cells from patients
have the potential to be reprogrammed to iPSCs, which can be
expanded in an undifferentiated state, or to be subjected to
lineage specific differentiation in response to a stimulus. In the
present study, we established a differentiation protocol for
FIGURE 3.miR-21 overexpression induces functional iPSCdifferentiation
into ECs in vitro and in vivo. A–I, iPSCs differentiated for 4 days in the pres-
ence of VEGF were transfected with miR-21 precursor (Pre-21) and the nega-
tive control (Pre-Ctrl). A–C, representative images of in vitro angiogenesis
assay (scale bar, 25 m) (A and B) and tube length quantification (C). D–I,
representative images (scale bar, 100 m) of in vivo angiogenesis assay and
quantification of capillaries positive for the endothelial markers VE-cadherin
(VE-cad) (D–F) and CD31 (G–I). The data presented are representative
of means  S.E. (error bars) of three independent experiments. *, p  0.05;
***, p 0.001.
FIGURE 4.miR-21 inhibition decreases functional differentiation of iPSCs
intoECs in vitroand in vivo.A–I, iPSCsdifferentiated for 4days inpresenceof
VEGF were transfected with miR-21 inhibitor (LNA-21) and the negative con-
trol (LNA-Ctrl).A–C, representative imagesof in vitro angiogenesis assay (scale
bar, 25 m) (A and B) and tube length quantification (C). D–I, representative
images (scale bar, 100m) of in vivo angiogenesis assay and quantification of
capillaries positive for theendothelialmarkers VE-cadherin (VE-cad) (D–F) and
CD31 (G–I). The data presented are representative ofmeans S.E. (error bars)
of three independent experiments. *, p 0.05; **, p 0.01; ***, p 0.001.
FIGURE 5. TGF-2 is a downstream target of miR-21. A–D, iPSCs differenti-
ated for 3 days with VEGF were transfected with miR-21 precursor (Pre-21),
inhibitor (LNA-21), and the negative controls of the miR-21 precursor (Pre-
Ctrl) and inhibitor (LNA-Ctrl), followed by quantitative RT-PCR assay (A and B)
and ELISAs (C and D) 48 h after transfection to assess TGF-2 expression and
secretion levels, respectively. The data presented are representative of
means S.E. (error bars) of three independent experiments. *, p 0.05.
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iPSCs, based on the use of collagen IV and 50 ng/ml VEGF.We
demonstrated that miR-21 is overexpressed in ECs derived
from iPSCs, as compared with the undifferentiated cells in gel-
atin, and mediates endothelial differentiation through target-
ing-specific pathways. Thus, our findings provide the basic
information for production of endothelial cells from iPSCs that
has a great potential in regenerative medicine.
Previously, Zeng et al. (24) stimulated Sca-1 vascular pro-
genitor cells with medium containing 10 ng/ml VEGF, and
Narazaki et al. (38) cultivated Flk1 progenitor cells with 100
ng/ml VEGF. In the present study, we tested several concentra-
tions ranging between these two extremes by using undifferen-
tiated iPSCs without predifferentiating the cells or selecting for
a specific progenitor population.We established that the treat-
ment of iPSCs with increasing concentrations of VEGF had an
effect on endothelial differentiation up to 50 ng/ml, which led
to a faster differentiation. Importantly, compared with previ-
ously described differentiation protocols, our protocol shows a
higher scale of EC marker induction, up to a 100-fold increase
in Flk1 expression, thus indicating better differentiation effi-
ciency. For instance, Narazaki et al. (38) showed that, in Flk1
progenitor cells, the effect of VEGF only led to a 20-fold
increase in EC marker expression. In conclusion, our protocol
allows the direct and efficient EC differentiation from undiffer-
entiated iPSCs in a relative short time and at the highest level, as
compared with the previously published protocols.
One of themain aims in this studywas to establish themolec-
ular mechanisms driving the differentiation of iPSCs to ECs.
Previous work on ES cells has shown that pluripotent cells and
cells differentiated to vascular ECs express different pools of
miRNAs (28). To our knowledge, there are no studies investi-
gating the miRNA profile during vascular differentiation of
iPSCs though recent publications (39). We decided to perform
miRNA arrays on iPSCs differentiated for 3 days with VEGF
and undifferentiated cells. We obtained a pool of differentially
expressed miRNAs and validated five of the most interesting
candidates. Among those, we decided to focus on miR-21, a
molecule previously reported in tumor angiogenesis and adipo-
genic differentiation of stem cells (13–17). It was found that
miR-21 could induce ECmarker expression in iPSCs prediffer-
entiated with VEGF, thus boosting the efficiency of differenti-
ation. These results were confirmed at a protein level and
through in vivo and in vitro functional angiogenesis assays. In
the study of Liu et al. (13), Matrigel plugs seeded with Pre-21-
and LNA-21-transfected human prostate cancer cells were
applied onto the chicken chorioallantoic membrane of 9-day-
old embryos to assess tumor angiogenesis. Supporting our find-
ings, the number of branches of microvessels were increased by
miR-21 overexpression and vice versa decreased by miR-21
inhibition, indicating a pro-angiogenic function of miR-21. In
our study, the in vivo angiogenesis process appears to be pro-
moted by miR-21 transfected cells. These results suggest that
miR-21 is a key modulator in the endothelial differentiation of
iPSCs. The screening for miR-21 potential targets is a challeng-
ing process, because prediction algorithms generate a high per-
centage of false positives.
FIGURE 6. TGF-2 is increased in ECs derived from iPSCs andpromotes this process.A–C, iPSCswere differentiatedwith VEGF for up to 7 days, followedby
quantitative RT-PCR assay to assess the expression of TGF-2 (A), TGF-RII (B), and TGF-RIII (C).D–L, iPSCs were treated for 7 days with 3 ng/ml TGF-2 (DM
TGF-2) or not (DM), followed by quantitative RT-PCR assay for the endothelial markers VE-cadherin and Flk1 (VE-cad, D and E), Western blotting for the
endothelialmarkers VE-cadherin (VE-cad) andCD31 (F, representative image;G, quantitative analysis), in vitro angiogenesis assay (representative images; scale
bar, 25 m) (H and I), and quantification of tube formation (J). The data presented are representative of means  S.E. (error bars) of three independent
experiments. *, p 0.05; **, p 0.01; ***, p 0.001.
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We showed that miR-21 induced TGF-2 expression and
secretion during EC differentiation. Importantly, TGF-2 neu-
tralization and knockdown inhibited the miR-21-mediated EC
marker induction, thus indicating the requirement of TGF-2
during this process. Accordingly, expression of TGF-2 and its
receptors appeared to be highly increased in iPSCs differenti-
ated with VEGF. TGF-2 secretion from iPSCs transfected
with Pre-21 appeared to be only in the scale of pg/ml. However,
because iPSCs continuously secrete TGF-2, which probably
exerts a paracrine action on neighboring cells, that concentra-
tion was sufficient to be effective in iPSC differentiation.
TGF- has been so far shown to induce smooth muscle dif-
ferentiation via Notch or SMAD2 and SMAD3 signaling in ES
cells (32) or in a neural crest stem cell line (40). Here, we report
that TGF-2 treatment is able to induce iPSC differentiation
specifically toward EC lineage, without affecting smooth mus-
cle gene expression. TGF-has been shown to bind toTGF-RI
and to induce phosphorylation of SMAD2/3, thereby inhibiting
proliferation, tube formation, and migration of ECs (41). How-
ever, so far there are no studies reporting the role of SMAD3 in
stem cell differentiation into ECs. The results reported in the
present study suggest the involvement of the TGF-2/SMAD3
pathway in the iPSC differentiation process; SMAD3 inhibition
not only abolished TGF-2 induction of EC markers, but also
reduced the baseline expression ofVE-cadherin, in the absence
of TGF-2 stimulation. This resultmay be explained by consid-
ering that SMAD3 is at the center of many other molecular
pathways, and it is not only a TGF-2 downstream effector. For
instance, it has been reported that SMAD2/3 is a downstream
effector of Activin/Nodal signaling that shares some biological
activities with TGF- (42); moreover, SMAD2/3 signaling has
been shown to keep vascular integrity through regulating
N-cadherin, VE-cadherin, and S1PR1 expression (43).
miR-21 has been previously shown to target PTEN through
Akt and ERK activation to induce tumor angiogenesis (13) and
through Akt to partly mediate TGF--induced endothelial to
mesenchymal transition (36). Our findings showed thatmiR-21
directly and specifically targets the PTEN/Akt pathway in EC
FIGURE 7. The effect of miR-21/TGF-2 on EC differentiation is mediated
by SMAD3 and VEGF secretion. A and B, iPSCs transfected withmiR-21 pre-
cursor (Pre-21) and precursor control (Pre-Ctrl) after 3 days of differentiation
in presence of VEGFwere treatedwith 1g/ml TGF-2 neutralizing antibody
(TGF-2 Ab) or IgG as a control; quantitative RT-PCR assay (A) and Western
blotting (B) were performed 5 h after transfection to assess the expression
levels of the EC markers VE-cadherin (VE-cad) and CD31, respectively. C–E,
iPSCs transfected with miR-21 precursor (Pre-21) and precursor control (Pre-
Ctrl) after 3 days of differentiation in presence of VEGF were infected with
shRNA specific for TGF-2 (shTGF-2) or nontargeting shRNAs (shNT) as a
control; quantitative RT-PCR assay was performed 48 h after infection to
assess the expression of TGF-2 (C), VE-cadherin (VE-cad) (D), and Flk1 (E). F,
iPSCs differentiated with () or without () TGF-2 for 7 days were treated
with SMAD3 inhibitor (SIS3) or DMSO as control, followed by quantitative
RT-PCRassay to assess the expressionofVE-cadherin (VE-cad).G, ELISAs show-
ing VEGF secretion in iPSCs treated for 7 days with TGF-2. H, iPSCs differen-
tiatedwith () or without () TGF-2 for 7 days were simultaneously treated
with VEGF neutralizing antibody (Ab VEGF) or IgG as a control (Ab VEGF),
followed by Western blotting to assess VE-cadherin (VE-cad) expression. The
data presented are representative of means S.E. (error bars) of three inde-
pendent experiments. *, p 0.05; **, p 0.01; ***, p 0.001.
FIGURE 8. miR-21 targets the PTEN/Akt pathway, which regulates iPSC
differentiation into ECs. A and B, iPSCs differentiated for 3 days with VEGF
were transfected with miR-21 precursor (Pre-21), inhibitor (LNA-21), and the
negative controls of the miR-21 precursor (Pre-Ctrl) and inhibitor (LNA-Ctrl),
followed by Western blotting 48 h after transfection to assess PTEN expres-
sion (A) and Ser(P)-473 Akt (P-Akt) and total Akt (tot Akt) expression (B). C and
D, the wild type or mutated reporter plasmid pGL3 for PTEN 3-UTR (pGL3-
PTEN-wt, C or pGL3-PTEN-mut, D) was co-transfected with miR-21 inhibitor
(LNA-21) and its control (LNA-Ctrl) in iPSCsdifferentiated for 3dayswithVEGF,
followed by luciferase assay 48 h after transfection. E, iPSCs differentiated for
3 days with VEGF, were infected with shRNA specific for PTEN (shPTEN) or
nontargeting shRNAs (shNT) as a control, followed by quantitative RT-PCR
assay to assess the expression of PTEN, VE-cadherin (VE-cad), and Flk1 48 h
after infection. F, iPSCs transfected with miR-21 inhibitor (LNA-21) and inhib-
itor control (LNA-Ctrl) after 3 days of differentiation in the presence of VEGF
were infectedwith shRNA specific for PTEN (shPTEN) or nontargeting shRNAs
(shNT) as a control; Western blotting was performed 48 h after infection to
assess the expression of PTEN and VE-cadherin (F). The data presented are
representative of means  S.E. (error bars) of three independent experi-
ments. *, p 0.05; ***, p 0.001.
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differentiation derived from iPSCs. Interestingly, it has been
shown that the PI3K/Akt signaling pathway plays a crucial role
inmany intracellular cascade events including tumor angiogen-
esis and tumor growth (44), and in particular, the PI3K/Akt
pathway has been reported to drive the shear-induced stem cell
differentiation into ECs (24). These results highlight that PTEN
knockdown is required to induce EC marker expression in
iPSCs differentiated to ECs and transfected with miR-21
inhibitor.
In a recently published study, it has been shown that Akt-
mediated Twist1 phosphorylation promotes epithelial-mesen-
chymal transition and breast cancer metastasis by modulating
its transcriptional target TGF-2; this leads to enhanced
TGF- receptor signaling, which in turnmaintains hyperactive
PI3K/Akt signaling (45). It is therefore possible that miR-21
activation of the PTEN/Akt pathway may induce Twist1
phosphorylation. Activation of Twist1 may target and induce
TGF-2 to mediate the endothelial differentiation of iPSCs.
PhosphorylatedTwist1may indeed have a key role inmediating
cross-talk between themiR-21/Akt and TGF-/Smad signaling
axes that supports endothelial differentiation of iPSCs. Other
additional pathways might be also involved in this process and
will be investigated in future.
In summary, the data presented in this study suggest that in
iPSCs predifferentiated with VEGF, miR-21 targets PTEN/Akt
and induces TGF-2, thereforemediating endothelial differen-
tiation (Fig. 9). Indeed, we established a new link between
VEGF, miR-21, and TGF-2 during the endothelial differenti-
ation of iPSCs. Elucidation of the molecular pathways involved
in the miR-21-mediated iPSC differentiation into ECs might
provide the basic information for stem cell therapy of vascular
diseases, e.g., tissue engineering and endothelial repair in dam-
aged vessels.
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